These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8210642)

  • 41. Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies.
    Klingemann HG
    Leuk Lymphoma; 1992 Dec; 8(6):421-9. PubMed ID: 1284296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Lymphoma; 1991; 5(4):263-71. PubMed ID: 27467849
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells--a mechanism affecting the human lung microenvironment?
    Zambello R; Trentin L; Enthammer C; Cipriani A; Agostini C; Semenzato G
    Clin Exp Immunol; 1996 Aug; 105(2):383-8. PubMed ID: 8706349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Ohno T
    J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells.
    Findley HW; Abdel Mageed A; Nasr SA; Ragab AH
    Cancer; 1988 Nov; 62(9):1928-31. PubMed ID: 3262410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
    Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [On traditional Chinese medicine-mediated biotherapy of leukemia].
    Li D
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Jan; 16(1):47-9. PubMed ID: 8732131
    [No Abstract]   [Full Text] [Related]  

  • 50. Augmentation of lymphokine-activated killer cell activity by lentinan.
    Tani M; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Noguchi K; Tamai M; Hotta T; Mizobata S
    Anticancer Res; 1993; 13(5C):1773-6. PubMed ID: 8267381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphokine-activated killer cell activity after cryopreservation.
    Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
    J Immunol Methods; 1989 Dec; 125(1-2):185-9. PubMed ID: 2607152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
    Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
    Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity.
    Chao TY; Jiang SY; Shyu RY; Yeh MY; Chu TM
    Br J Cancer; 1997; 75(9):1284-90. PubMed ID: 9155047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
    Archimbaud E; Bailly M; Doré JF
    Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
    Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
    Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
    Yaron I; Zakheim AR; Oluwole SF; Hardy MA
    Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
    [No Abstract]   [Full Text] [Related]  

  • 59. Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells.
    Tahara T; Iseki R; Morishima Y; Yokomaku S; Ohno R; Saito H
    Jpn J Cancer Res; 1988 Mar; 79(3):390-9. PubMed ID: 3131287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.